Here, we show that the EGFR inhibitor gefitinib and the mTOR inhibitor RAD001 when used in combination improve effectiveness of the treatment in HER2 overexpressing breast cancers that results in impediment of cancer growth. Here, EGFR is linked to breast cancer.